|
| Press Releases |
|
 |
|
| Friday, August 28, 2020 |
|
|
中國生物製藥公佈2020年中期業績 |
| 中國領先的創新研發驅動型醫藥集團—中國生物製藥有限公司（「中國生物製藥」或「公司」，連同附屬公司統稱「集團」）（股票編號：1177）公佈截至2020年6月30日止六個月（「回顧期」）之未經審核財務業績。 more info >> |
|
|
Sino Biopharm Announces 2020 Interim Results |
| Sino Biopharmaceutical Limited ("Sino Biopharm" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading, innovative research and development ("R&D") driven pharmaceutical conglomerate in the PRC, has announced its unaudited interim results for the six months ended 30 June 2020 (the "review period"). more info >> |
|
| Thursday, May 28, 2020 |
|
|
中国生物制药公布2020年第一季度业绩 |
| 中国领先的创新研发驱动型医药集团—中国生物制药有限公司（「中国生物制药」或「公司」，连同附属公司统称「集团」）（股票编号：1177）公布截至2020年3月31日止三个月（「回顾期」）之未经审核财务业绩。 more info >> |
|
|
中國生物製藥公佈2020年第一季度業績 |
| 中國領先的創新研發驅動型醫藥集團—中國生物製藥有限公司（「中國生物製藥」或「公司」，連同附屬公司統稱「集團」）（股票編號：1177）公佈截至2020年3月31日止三個月（「回顧期」）之未經審核財務業績。 more info >> |
|
| Thursday, August 29, 2019 |
|
|
中國生物製藥公佈2019年中期業績 |
中國領先的創新驅動型醫藥集團—中國生物製藥有限公司（「中國生物製藥」或「公司」，連同附屬公司統稱「集團」）（股票編號：1177）今天公佈截至2019年6月30日止六個月（「回顧期」）之未經審核財務業績。
more info >> |
|
| Thursday, May 28, 2020 |
|
|
Sino Biopharmaceutical Announces 2020 First Quarterly Results |
| Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading, innovative research and development ("R&D") driven pharmaceutical conglomerate in the PRC, has announced its unaudited first quarterly results for the three months ended 31 March 2020 ("the review period"). more info >> |
|
| Tuesday, May 26, 2020 |
|
|
中国生物制药与康方生物共同开发派安普利新药上市申请获国家药品监督管理局受理 |
| 中国领先的创新研发驱动型医药集团 — 中国生物制药有限公司（股份代号：1177）宣布，与致力研究、开发、生产及商业化全球病人可负担的创新抗体新药的生物制药公司康方生物科技（开曼）有限公司（「康方生物」；股份代号：9926） more info >> |
|
|
中國生物製藥與康方生物共同開發派安普利新藥上市申請獲國家藥品監督管理局受理 |
| 中國領先的創新研發驅動型醫藥集團 — 中國生物製藥有限公司（股份代號：1177）宣佈，與致力研究、開發、生產及商業化全球病人可負擔的創新抗體新藥的生物製藥公司康方生物科技（開曼）有限公司（「康方生物」；股份代號：9926） more info >> |
|
|
New Drug Application of Penpulimab Co-developed by Sino Biopharmaceutical and Akeso Accepted by the National Medical Products Administration |
| Sino Biopharmaceutical Limited (HKEX: 1177), a leading, innovative research and development ("R&D") driven pharmaceutical conglomerate in the PRC, has announced that the new drug application of the anti PD-1 monoclonal antibody drug more info >> |
|
| Tuesday, May 19, 2020 |
|
|
中国生物制药与康方生物共同开发派安普利单抗联合安罗替尼一线治疗晚期肝癌的临床试验数据获ASCO年会接受呈列 |
| 中国领先的创新研发驱动型医药集团 — 中国生物制药有限公司（股份代号：1177）宣布，与康方生物科技（开曼）有限公司（「康方生物」；股份代号：9926），共同开发及商业化的派安普利单抗（AK105，PD-1单抗）联合安罗替尼一线治疗晚期肝细胞癌的临床疗效和安全性二期研究数据摘要，获即将召开的2020年美国临床肿瘤学会（ASCO）年会接受以海报形式呈列。 more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Kincora Receives Option Payment for Divestment of Mongolian Assets
May 19, 2026 17:59 HKT/SGT
|
|
|
'Young at Heart' 3DG Jewellery Brand Tour Kicks Off in Wuhan
May 19, 2026 15:44 HKT/SGT
|
|
|
「Young at Heart 心齡無界」金至尊珠寶品牌巡展首站於武漢璀璨啟幕
May 19, 2026 15:44 HKT/SGT
|
|
|
「Young at Heart 心龄无界」金至尊珠宝品牌巡展首站于武汉璀璨启幕
May 19, 2026 15:44 HKT/SGT
|
|
|
Carbonverse打造「碳資產+數字錢包+使用即挖礦」新生態
May 19, 2026 15:41 HKT/SGT
|
|
|
Vaiz introduces agile project management tools as teams leave Jira for simpler alternatives
May 19, 2026 15:00: JST
|
|
|
Vaiz introduces agile project management tools as teams leave Jira for simpler alternatives
May 19, 2026 14:00 HKT/SGT
|
|
|
SMBC Group, Fujitsu and SoftBank agree on alliance to build Japan-made platform for sustainable healthcare
May 19, 2026 13:37 JST
|
|
|
SMBCグループ、富士通、ソフトバンク、健康・医療分野での業務提携に合意し、持続可能な医療の実現に向けて国産ヘルスケア基盤を構築
May 19, 2026 11:15: JST
|
|
|
Anson Resources Engineering Study Confirms Green River as a Future Low-Cost Producer
May 19, 2026 10:40 HKT/SGT
|
|
|
'Hong Kong Cinema @ CANNES 2026': Hong Kong's role as a bridge between global and Asian film markets
May 19, 2026 10:16 HKT/SGT
|
|
|
宇樹科技、雲深處IPO進程提速 首程控股（697.HK）機器人投資進入價值驗證期
May 19, 2026 09:05 HKT/SGT
|
|
|
Unitree Robotics and DEEP Robotics Accelerate IPO Progress; Shoucheng Holdings' Robotics Investments Enter a Value Validation Phase
May 19, 2026 08:58 HKT/SGT
|
|
|
Shoucheng Holdings (697.HK): Robotics Investments Near Monetization Window as Dividends and Buybacks Strengthen Shareholder Returns
May 19, 2026 08:52 HKT/SGT
|
|
|
首程控股（697.HK）機器人投資即將進入兌現窗口 分紅回購強化股東回報
May 19, 2026 08:40 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
